Related Experiment Videos
Development in anticoagulant therapy
F F van Doormaal1, H R Büller, S Middeldorp
1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. F.F.vanDoormaal@amc.uva.nl
Abstract:
Venous thromboembolism is an important clinical problem. Cancer patients have higher risk to develop venous thrombosis and vice versa. The treatment consists of heparin followed by vitamin K antagonists. Both agents have several limitations. Especially in cancer patients, vitamin K antagonists cause bleeding or recurrence of VTE because of a small therapeutic window. Monotherapy with low-molecular weight heparin seems to cause less of these complications in cancer patients compared to vitamin K antagonists. Besides, the drug is thought to have anti-cancer properties. Several novel anticoagulants are being developed and are undergoing clinical evaluation. New anticoagulants should also be evaluated on the effect on progression of cancer and cancer-related survival.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care